You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

EIGHT, the global educational initiative on Hemophilia A and its treatment

Experts from all over the world attended the EIGHT 2018 Conference in Budapest, Hungary on 12-13 October

read more 

EVENTS

Kedrion Biopharma participates in the Mother and Child Conference in Moscow

A 50 years of Anti-D dedicated programme presented at the main Russian congress of Gynecology and Obstetrics

read more 

EVENTS

Kedrion Joins Annual PNS Conference on Neurology

The company took part in the event with a booth and a delegation of 40 int’l guests

read more 

  1. PLASMA & BIOTHERAPIES - 16-09-2016

    Humanitarian Factor IX donation to Afghanistan

    Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries

    read more 

  2. PLASMA & BIOTHERAPIES - 13-09-2016

    Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment

    BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017

    read more 

  3. EVENTS - 26-07-2016

    SIPPET Study was WHF 2016 World Congress highlight

    A Kedrion, Grifols and LFB supported symposium featured a lecture by Dr. Manuel Carcao

    read more 

  4. CORPORATE - 17-06-2016

    Kedrion Biopharma consolidates presence on Russian market

    Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant

    read more 

Pages

For more information please contact: pressoffice@kedrion.com